Total Payments
$11,338
2024 Payments
$2,029
Companies
31
Transactions
602
Medicare Patients
1,187
Medicare Billing
$526,231
Payment Breakdown by Category
Food & Beverage$11,226 (99.0%)
Education$111.96 (1.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,226 | 597 | 99.0% |
| Education | $111.96 | 5 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $2,027 | 105 | $0 (2024) |
| ABBVIE INC. | $1,808 | 106 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,578 | 111 | $0 (2024) |
| PFIZER INC. | $1,143 | 40 | $0 (2024) |
| GlaxoSmithKline, LLC. | $940.36 | 57 | $0 (2024) |
| Janssen Biotech, Inc. | $701.42 | 39 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $522.52 | 29 | $0 (2023) |
| Horizon Therapeutics plc | $512.01 | 19 | $0 (2023) |
| UCB, Inc. | $330.85 | 20 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $277.42 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,029 | 78 | ABBVIE INC. ($685.88) |
| 2023 | $1,960 | 91 | Novartis Pharmaceuticals Corporation ($470.21) |
| 2022 | $2,225 | 119 | Novartis Pharmaceuticals Corporation ($438.09) |
| 2021 | $2,469 | 155 | Amgen Inc. ($588.24) |
| 2020 | $1,537 | 97 | Amgen Inc. ($417.03) |
| 2019 | $922.19 | 56 | Horizon Therapeutics plc ($179.65) |
| 2018 | $141.23 | 3 | Genentech USA, Inc. ($100.00) |
| 2017 | $54.25 | 3 | Amgen Inc. ($28.41) |
All Payment Transactions
602 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.05 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $32.83 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Inflammation | ||||||
| 12/06/2024 | Organon Llc | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.90 | General |
| Category: Immunology | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.76 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $27.83 | General |
| 11/06/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $30.60 | General |
| Category: IMMUNOLOGY | ||||||
| 10/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $30.84 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: IMMUNOLOGY | ||||||
| 10/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $32.23 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.27 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $30.59 | General |
| Category: IMMUNOLOGY | ||||||
| 09/30/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/24/2024 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Immunology | ||||||
| 09/20/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $26.10 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 09/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: IMMUNOLOGY | ||||||
| 09/05/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: Inflammation | ||||||
| 09/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: IMMUNOLOGY | ||||||
| 09/04/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/03/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: Inflammation | ||||||
| 08/30/2024 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Food and Beverage | In-kind items and services | $29.50 | General |
| Category: Biosimilars | ||||||
| 08/23/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 302 | 6,407 | $380,158 | $128,201 |
| 2022 | 7 | 297 | 931 | $190,729 | $71,437 |
| 2021 | 5 | 292 | 5,543 | $382,493 | $158,714 |
| 2020 | 5 | 296 | 6,798 | $393,631 | $167,879 |
Total Patients
1,187
Total Services
19,679
Medicare Billing
$526,231
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 186 | 661 | $140,793 | $58,651 | 41.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 13 | 5,500 | $198,000 | $57,636 | 29.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 58 | $19,430 | $3,474 | 17.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 29 | $8,410 | $3,416 | 40.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 15 | 22 | $7,370 | $2,708 | 36.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 28 | 88 | $4,048 | $1,698 | 41.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 49 | $2,107 | $617.80 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 184 | 654 | $139,302 | $57,832 | 41.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 24 | 96 | $32,160 | $6,131 | 19.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 21 | $6,090 | $2,725 | 44.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 31 | 80 | $3,680 | $1,687 | 45.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $4,830 | $1,522 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 16 | $2,560 | $911.44 | 35.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 49 | $2,107 | $628.92 | 29.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 205 | 774 | $164,862 | $80,325 | 48.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2021 | 12 | 4,609 | $165,924 | $63,069 | 38.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 25 | 103 | $34,505 | $7,101 | 20.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 29 | 36 | $10,440 | $5,484 | 52.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $6,762 | $2,735 | 40.4% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2020 | 12 | 5,977 | $209,146 | $94,172 | 45.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 192 | 650 | $132,600 | $58,089 | 43.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 51 | 75 | $21,150 | $8,107 | 38.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 26 | 81 | $26,325 | $5,423 | 20.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $4,410 | $2,088 | 47.3% |
About Dr. Peter Mohai, MD
Dr. Peter Mohai, MD is a Rheumatology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831185966.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Mohai, MD has received a total of $11,338 in payments from pharmaceutical and medical device companies, with $2,029 received in 2024. These payments were reported across 602 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($11,226).
As a Medicare-enrolled provider, Mohai has provided services to 1,187 Medicare beneficiaries, totaling 19,679 services with total Medicare billing of $526,231. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Seattle, WA
- Active Since 09/23/2005
- Last Updated 12/16/2024
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1831185966
Products in Payments
- Enbrel (Biological) $1,371
- RINVOQ (Biological) $1,219
- COSENTYX (Biological) $1,073
- XELJANZ (Drug) $997.00
- BENLYSTA (Biological) $937.07
- ORENCIA (Biological) $522.52
- KRYSTEXXA (Biological) $512.01
- COSENTYX (Drug) $463.19
- EVENITY (Biological) $406.06
- TREMFYA (Drug) $385.09
- Cimzia (Drug) $307.49
- SKYRIZI (Biological) $305.22
- LUPKYNIS (Drug) $277.42
- KEVZARA (Biological) $262.74
- SAPHNELO (Biological) $230.32
- REMICADE (Biological) $194.34
- TALTZ (Drug) $145.25
- Actemra (Biological) $118.85
- SIMPONI ARIA (Biological) $103.84
- Arcalyst (Drug) $100.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Seattle
Philip Mease, Md, MD
Rheumatology — Payments: $2.9M
Rheumatology $2.9M
Jane Buckner, Md, MD
Rheumatology — Payments: $71,520
Rheumatology $71,520
Dr. Kwanghoon Han, Md, MD
Rheumatology — Payments: $17,137
Rheumatology $17,137
Dr. Namrata Singh, M.d, M.D
Rheumatology — Payments: $15,855
Rheumatology $15,855
Myriam Guevara, Md, MD
Rheumatology — Payments: $14,597
Rheumatology $14,597
Steven Overman, Md, MD
Rheumatology — Payments: $13,800
Rheumatology $13,800